Results 1 to 10 of about 5,442 (125)

B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think [PDF]

Kidney Medicine
B-cell depletion with the chimeric anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of glomerular diseases. Obinutuzumab, a type II glycoengineered anti-CD20 humanized monoclonal antibody, is increasingly being employed as an ...
Decimo Silvio Chiarenza, Enrico E. Verrina, Carolina Bigatti, Gianluca Caridi, Agnese Spennacchio, Xhuliana Kajana, Massimiliano De Bortoli, Paolo Cravedi, Andrea Angeletti   +8 more
doaj   +2 more sources

Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study [PDF]

Journal of Pharmaceutical Health Care and Sciences
Background Premedication with corticosteroids is recommended for prophylaxis against infusion-related reactions (IRRs) caused by obinutuzumab despite a lack of solid evidence regarding the dose of corticosteroids.
Tatsuya Ohtsubo, Kazuhiro Yamamoto, Saori Matumoto, Kaori Ito, Yuzuka Sasa, Kosuke Tomishima, Satoshi Dote, Katuya Makihara, Yoshinori Wakasugi, Tsutomu Mitsuie, Kouhei Yamagiwa, Kazuo Sato, Hiroki Hasegawa, Nobuhiko Uoshima, Yumi Kitahiro, Kanji Tomogane   +15 more
doaj   +2 more sources

Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study [PDF]

Frontiers in Immunology
ObjectiveThis study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).MethodsFifty-five patients with pMN treated with obinutuzumab were respectively ...
Xi Cheng, Zhen-feng Zheng, Yan Qi, Xin Cao, Xi-qian Gao, Ying-xin Fang, Li Wei, Wen-ya Shang, Tie-kun Yan, Jun-ya Jia, Peng-cheng Xu, Qiu-hua Gu   +11 more
doaj   +2 more sources

Safety assessment of obinutuzumab: Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025. [PDF]

PLoS ONE
BackgroundObinutuzumab is the first glycosylated type II anti-CD20 monoclonal antibody for the treatment of lymphocytic leukemia and follicular lymphoma.
Xiangpeng Li, Haonan Liang, Ping Leng, Zhanqi Cao   +3 more
doaj   +2 more sources

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [PDF]

Oncology and Therapy
Introduction Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted indirect comparison (MAIC) can be
Talha Munir, Nicolás Martinez-Calle, Sheng Xu, Keri Yang, Xiaoyun Ge, Ayad K. Ali, Leyla Mohseninejad, Balázs Dobi, Pal Rakonczai, Han Ma, Rhys Williams, Wassim Aldairy, Nicole Lamanna   +12 more
doaj   +2 more sources

Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review [PDF]

Frontiers in Immunology
Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Kun Kou, Qiaolin Zhou, Lijun Du, Fang Xu
doaj   +2 more sources

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

BMC Cancer, 2022
Background Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other ...
Nicole Bourrier, Ivan Landego, Oliver Bucher, Mandy Squires, Erin Streu, Irena Hibbert, Theresa Whiteside, Spencer B. Gibson, Marc Geirnaert, James B. Johnston, David E. Dawe, Versha Banerji   +11 more
doaj   +1 more source

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica, 2022
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G. Gribben, Kevin Kwei, Sandra Dai, Emily Hsu, James P. Dean, Ian W. Flinn   +15 more
doaj   +1 more source

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

iScience, 2021
Summary: The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their mechanisms of action, with obinutuzumab evoking greater direct B cell death.
Jennifer Edelmann, Arran D. Dokal, Emma Vilventhraraja, Karlheinz Holzmann, David Britton, Tetyana Klymenko, Hartmut Döhner, Mark Cragg, Andrejs Braun, Pedro Cutillas, John G. Gribben   +10 more
doaj   +1 more source

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Frontiers in Pharmacology, 2023
Introduction: Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison with obinutuzumab.Methods: A ...
Annamaria Mascolo, Annamaria Mascolo, Raffaella Di Napoli, Raffaella Di Napoli, Nunzia Balzano, Nunzia Balzano, Elena D’Alessio, Imma Izzo, Imma Izzo, Francesco Rossi, Francesco Rossi, Giuseppe Paolisso, Annalisa Capuano, Annalisa Capuano, Liberata Sportiello, Liberata Sportiello   +15 more
doaj   +1 more source